**Table 4 Breakpoint values of antimicrobial agents according to CLSI, 2011 and phenotypic antimicrobial susceptibility profiles of 15** _**S. enterica**_ **isolates used**
**in this study**



**Antibiotic class** **Antimicrobial agent** **Conc. (μg)** **Zone diameter (mm)** _**S.**_ **Typhimu‑**
**rium (9)**



_**S.**_ **Enteritidis**
**(2)**



_**S.**_ **Kentucky**
**(1)**



_**S.**_ **Paratyphi**
**A (3)**



**Total** _**Salmonella**_ **(15)**



**R** **I** **S** **R** **I** **S** **R** **I** **S** **R** **I** **S** **R** **I** **S** **R** **I** **S**



Penicillin Amoxycillin–clavulanic acid 20 ≤ 13 14–17 ≥ 18 5 4 - - 2 - 1 - - 2 1 - 8 (53%) 7 (47%) 


Ampicillin 10 ≤ 13 14–16 ≥ 17 7 2 - 2 - - 1 - - 3 - - 13 (87%) 2 (13%) 
Cefotaxime 30 ≤ 22 23–25 ≥ 26 7 1 1 2 - - - 1 - 3 - - 12 (80%) 2 (13%)

Cefpodoxime 20 ≤ 17 18–20 ≥ 21 7 2 - 1 1 - - 1 - 1 2 - 9 (60%) 6 (40%) 


Cephalosporin Cefotaxime 30 ≤ 22 23–25 ≥ 26 7 1 1 2 - - - 1 - 3 - - 12 (80%) 2 (13%) 1 (7%)



Ceftazidime 30 ≤ 17 18–20 ≥ 21 3 5 1 - 2 - - 1 - 1 2 - 4 (26%) 10 (67%) 1 (7%)



Ceftriaxone 30 ≤ 19 20–22 ≥ 23 3 6 - - 2 - - 1 - 2 1 - 5 (33%) 10 (67%) 


Miscellaneous Chloramphenicol 30 ≤ 12 13–17 ≥ 18 - 5 4 - - 2 - 1 - - 1 2 - 7 (47%) 8 (53%)



Colistin 10 ≤ 11 12–13 ≥ 14 - - 9 - - 2 - - 1 - - 3 - - 15 (100%)



Fluoroquinolone Ciprofloxacin 5 ≤ 15 16–20 ≥ 21 - 3 6 - 1 1 - 1 - - - 3 - 5 (33%) 10 (67%)



Enrofloxacin 5 ≤ 17 18–20 ≥ 21 1 7 1 - 1 1 - 1 - - 2 1 1 (7%) 11 (73%) 3 (20%)



Nalidixic acid 30 ≤ 13 14–18 ≥ 19 3 6 - 1 1 - 1 - - - 3 - 5 (33%) 10 (67%) 


Aminoglycoside Streptomycin 10 ≤ 11 12–14 ≥ 15 2 7 - 1 1 - 1 - - - 2 1 4 (26%) 10 (67%) 1 (7%)



Tetracycline Tetracycline 30 ≤ 11 12–14 ≥ 15 3 6 - 2 - - 1 - - - 3 - 6 (40%) 9 (60%) 


Sulphonamide Trimethoprim/sulphamethoxazole 25 ≤ 4 3 ≥ 2 4 2 3 1 1 - 1 - - 2 1 - 8 (53%) 4 (26%) 3 (20%)



_S_ sensitive, _I_ intermediate, _R_ resistant


